Advertisement
U.S. Markets closed

Altamira Therapeutics Ltd. (CYTO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Visitors trend2W10W9M
0.5049-0.0141 (-2.72%)
At close: 04:00PM EST
0.5200 +0.02 (+2.99%)
After hours: 07:49PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5190
Open0.5100
Bid0.3500 x 200
Ask0.6305 x 200
Day's Range0.4900 - 0.5100
52 Week Range0.4500 - 17.2000
Volume20,636
Avg. Volume377,087
Market Cap1.908M
Beta (5Y Monthly)2.41
PE Ratio (TTM)0.28
EPS (TTM)1.8200
Earnings DateSep 24, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.32
  • GlobeNewswire

    Altamira Therapeutics Provides Update on Nasdaq Listing

    Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq’s Listing Rules, which requires listed securities to maintain a minimum bid price of $1.00 per share, because the bid price of the Company’s listed securities has close

  • GlobeNewswire

    Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

    Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Certification to ISO 13485 extended to also include production process Supports Bentrio growth strategy together with strategic contract manufacturer and expanding network of international distributors Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also produc